Dublin, Ireland (PRWEB) March 22, 2013
Research and Markets has announced the addition of "Research on China’s FISH Probe (Fluorescent in Situ Hybridization Probe) Industry, 2013-2017" market report to their offering.
According to Huidian’s market research, the output value of China’s FISH probe market in 2012 was about CNY 20 million to CNY 30 million; with the improvement of people’s living standard and medical conditions in the future, FISH probe products will be more and more used in medical diagnosis.
The main brands of China’s FISH probe industry are GP, Abbott, LBP, Zhongsheng Damaidi, BioChina and Zhejiang Orient Gene. In 2012, the FISH probes of GP and Abbott occupied the monopoly position in domestic market, and the market share was about 51% and 32 % respectively, and the market share of LBP was about 13%.
At present, the annual sales of China’s clinical diagnostic reagent market has developed to CNY 3 billion to CNY 4 billion, of which, clinical biochemistry accounted for 30%, the immune products accounted for 25%, and the blood products and urine analysis products ranged from 8% to 10% and 3% to 5% respectively, the microbial products accounted for 2% to 3%. According to the estimate of experts, the annual growth rate of domestic clinical diagnostic market will reach 15% to 20% in the next five years.
Huidian Research predicts that the growth rate of FISH probe market will be not lower than 15% in the future. Therefore, it is estimated that the output value in this market will be about CNY 32 million in 2013, and this number will reach CNY 56 million by 2017.
Key Topics Covered:
1. Overview of China’s FISH Probe Products
2. Development Envi
Copyright©2012 Vocus, Inc.
All rights reserved